In a metastatic melanoma cohort, higher burden of copy number loss was observed in non-responders compared to responders on cytotoxic T-lymphocyte associated protein 4 (CTLA-4) blockade [41]. This evidence concerns the gene CTLA4 and metastatic melanoma.